Literature DB >> 19270495

Increase of telomerase activity and hTERT expression in myelodysplastic syndromes.

Federica Briatore1, Giuseppina Barrera, Stefania Pizzimenti, Cristina Toaldo, Chiara Della Casa, Stefano Laurora, Piergiorgio Pettazzoni, Mario Umberto Dianzani, Dario Ferrero.   

Abstract

Telomerase enzyme, containing a catalytic subunit, the human telomerase reverse transcriptase (hTERT), and a small integral RNA component, synthesises the telomeres, the ends of eukaryotic chromosomes. Inhibition of telomerase activity leads the cells to senescence and death. Myelodysplastic syndromes (MSD) are hematological malignancies characterized by peripheral blood cytopenia and ineffective hematopoiesis. Telomerase activity and hTERT expression in MDS patients were independently investigated by different groups obtaining contradictory results. We analyzed telomerase activity and hTERT expression in the bone marrow of ten control, 15 MDS patients and two patients with AML, likely evolved from a previous MDS. Moreover, the expression of c-myc, mad1, p53 (transcription factors involved in hTERT expression regulation), has been investigated. Telomerase activity and hTERT expression increased in the MDS patients with respect to the controls. The analysis of the MDS subgroups, indicated that patients with more severe disease demonstrated significantly higher levels of hTERT expression and telomerase activity with respect to the patients with more favorable disease. c-Myc and p53 expressions were not significantly different between controls and MDS patients, whereas mad1 expression was increased in MDS patiens, particularly in those with more favorable disease. We hypothesize that mad1 increase can contribute to reduce the hTERT expression in the early stage of disease and we suggest that hTERT expression and telomerase activity, whether confirmed in larger series of cases could support other parameters in the diagnosis and stadiation of MDS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270495     DOI: 10.4161/cbt.8.10.8130

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  10 in total

1.  Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.

Authors:  Enrica Rampazzo; Laura Bonaldi; Livio Trentin; Carlo Visco; Sonia Keppel; Silvia Giunco; Federica Frezzato; Monica Facco; Elisabetta Novella; Ilaria Giaretta; Paola Del Bianco; Gianpietro Semenzato; Anita De Rossi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.

Authors:  Hei Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Kyu Hyun Park; Tae Soo Kim; Jin Ju Kim; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

Review 3.  Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Authors:  Adam J Linley; Murrium Ahmad; Robert C Rees
Journal:  Int J Hematol       Date:  2011-03-01       Impact factor: 2.490

Review 4.  New Approaches to Myelodysplastic Syndrome Treatment.

Authors:  Alexandre Bazinet; Guillermo Montalban Bravo
Journal:  Curr Treat Options Oncol       Date:  2022-03-23

5.  Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia.

Authors:  Beate Vajen; Kathrin Thomay; Brigitte Schlegelberger
Journal:  Cancers (Basel)       Date:  2013-07-04       Impact factor: 6.639

Review 6.  The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.

Authors:  Limengmeng Wang; Haowen Xiao; Xing Zhang; Chong Wang; He Huang
Journal:  J Hematol Oncol       Date:  2014-08-20       Impact factor: 17.388

7.  Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.

Authors:  L Yang; A Mailloux; D E Rollison; J S Painter; J Maciejewski; R L Paquette; T P Loughran; K McGraw; H Makishima; R Radhakrishnan; S Wei; X Ren; R Komrokji; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2012-10-17       Impact factor: 11.528

Review 8.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene.

Authors:  Muhammad Khairul Ramlee; Jing Wang; Wei Xun Toh; Shang Li
Journal:  Genes (Basel)       Date:  2016-08-18       Impact factor: 4.096

9.  MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells.

Authors:  Wen Dong; Lei Wu; Houfang Sun; Xiubao Ren; Pearlie K Epling-Burnette; Lili Yang
Journal:  Oncotarget       Date:  2016-11-01

Review 10.  Alternative Splicing of Human Telomerase Reverse Transcriptase (hTERT) and Its Implications in Physiological and Pathological Processes.

Authors:  Anna A Plyasova; Dmitry D Zhdanov
Journal:  Biomedicines       Date:  2021-05-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.